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Abstract
Background. Two types of mentalization-based treatment (MBT), day hospital MBT (MBT-
DH) and intensive outpatient MBT (MBT-IOP), have been shown to be effective in treating
patients with borderline personality disorder (BPD). This study evaluated trajectories of
change in a multi-site trial of MBT-DH and MBT-IOP at 36 months after the start of
treatment.
Methods. All 114 patients (MBT-DH n = 70, MBT-IOP n = 44) from the original multicentre
trial were assessed at 24, 30 and 36 months after the start of treatment. The primary outcome
was symptom severity measured with the Brief Symptom Inventory. Secondary outcome mea-
sures included borderline symptomatology, personality and interpersonal functioning, quality
of life and self-harm. Data were analysed using multilevel modelling and the intention-to-treat
principle.
Results. Patients in both MBT-DH and MBT-IOP maintained the substantial improvements
made during the intensive treatment phase and showed further gains during follow-up. Across
both conditions, 83% of patients improved in terms of symptom severity, and 97% improved
on borderline symptomatology. No significant differences were found between MBT-DH and
MBT-IOP at 36 months after the start of treatment. However, trajectories of change were dif-
ferent. Whereas patients in MBT-DH showed greater improvement during the intensive treat-
ment phase, patients in MBT-IOP showed greater continuing improvement during follow-up.
Conclusions. Patients in both conditions showed similar large improvements over the course
of 36 months, despite large differences in treatment intensity. MBT-DH and MBT-IOP were
associated with different trajectories of change. Cost-effectiveness considerations and predic-
tors of differential treatment outcome may further inform optimal treatment selection.
Previous studies have provided evidence for the efficacy of two types of mentalization-based
treatment (MBT) for borderline personality disorder (BPD): day hospital MBT (MBT-DH),
a treatment involving day hospitalization of patients 5 days per week, and intensive outpatient
MBT (MBT-IOP), an outpatient treatment program conducted 2 days per week (Bales et al.,
2012, 2014; Barnicot & Crawford, 2019; Bateman & Fonagy, 1999, 2001, 2008, 2009; Jørgensen
et al., 2013, 2014; Kvarstein et al., 2015; Laurenssen et al., 2018). However, only one trial has
directly compared the two treatment programs. Smits et al. (2019) found that both MBT-DH
and MBT-IOP were associated with substantial improvements on both primary and secondary
outcome measures, representing moderate-to-large effect sizes 18 months after the start of
treatment. Although MBT-DH was not superior to MBT-IOP in terms of changes on the pri-
mary outcome measure (symptom severity), MBT-DH showed a trend towards superiority on
secondary outcome measures, particularly on measures of relational functioning. Longer-term
follow-up data are thus needed to further determine the relative efficacy of MBT-DH and
MBT-IOP.
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As MBT aims to improve mentalizing, and improvements in
mentalizing are thought to underlie ‘broaden-and-build’ cycles
leading to improved emotion regulation, feelings of autonomy
and agency, and improved capacity for relatedness (Fredrickson,
2001; Luyten & Fonagy, 2014), patients in MBT are expected to
show ongoing improvement after treatment termination.
Consistent with this hypothesis, previous follow-up studies have
shown that the gains made during the intensive treatment
phase of MBT-DH were maintained and that patients continued
to improve over 18-month and 5-year follow-up periods for the
MBT-DH program (Bales et al., 2014; Bateman & Fonagy, 2001,
2008), although for MBT-IOP, ongoing improvement was not
found in one 18-month follow-up study (Jørgensen et al., 2014).
Several studies have focused on the impact of treatment
modality or intensity on treatment outcome in BPD. For instance,
a non-randomized study by Bartak et al. (2011) investigated the
differential effectiveness of three treatment modalities (inpatient,
day hospital and outpatient treatment) and consequent varying
degrees of treatment intensity for cluster B personality disorders,
yielding somewhat inconclusive results. Although patients
improved in all treatment modalities, at 18-month follow-up,
inpatient treatment was associated with marginally significant
better outcomes in terms of psychiatric symptoms, compared
with outpatient treatment. There were no differences in terms
of quality of life and interpersonal functioning (Bartak et al.,
2011). At 60-month follow-up, inpatient treatment was associated
with slightly better outcomes compared with outpatient treatment
in terms of quality of life, but not on other outcome measures
(Horn et al., 2016). Another non-randomized study, by Chiesa,
Fonagy, Holmes, and Drahorad (2004), showed significantly bet-
ter outcomes in a heterogeneous sample of patients with person-
ality disorder in a step-down program compared with
longer-term inpatient treatment and general psychiatric services.
At 1- and 2-year follow-up, patients in the step-down group
showed a greater improvement in symptom severity, social func-
tioning and self-harming behaviours and reported less use of out-
patient treatment and readmissions to psychiatric services after
discharge. These findings were maintained at 6-year follow-up
(Chiesa, Fonagy, & Holmes, 2006). Nevertheless, a more recent
meta-analysis of psychotherapy for BPD by Cristea et al. (2017)
found that neither treatment duration nor treatment intensity
was related to treatment outcome. A number of recent rando-
mized controlled trials are addressing the issue of treatment inten-
sity (Juul et al., 2019; McMain et al., 2018), but these studies are
still ongoing. Clearly, more research in this area is needed.
The current paper reports on the findings at 3-year follow-up
from the abovementioned randomized clinical trial comparing
MBT-DH and MBT-IOP for patients with BPD (Smits et al.,
2019). Because MBT-DH and MBT-IOP differ markedly in
terms of treatment intensity, we expected that the tendency for
MBT-DH to be superior to MBT-IOP would be more pronounced
at 36-month follow-up, given the substantially higher dose of
treatment.
Method
This study was approved by the Medical Ethical Committee of
Erasmus Medical Center, Rotterdam, the Netherlands
(NL38571.078.12). A total of 114 patients from three sites in
the Netherlands were randomized to MBT-DH (n = 70) or
MBT-IOP (n = 44) and received treatment as allocated for a max-
imum duration of 18 months. Inclusion and exclusion criteria,
patient characteristics and randomization procedures have been
described in detail by Laurenssen et al. (2014). All 114 patients
included in the 18-month treatment outcome study (Fig. 1)
were approached again for long-term follow-up assessments at
24, 30 and 36 months after the start of treatment. Written
informed consent was obtained from all patients.
Outcome measures
The primary outcome measure was symptom severity as assessed
by the Global Severity Index of the Brief Symptom Inventory
(BSI; De Beurs, 2011; Derogatis, 1975). Secondary outcomes
included severity of borderline symptoms as measured with the
Personality Assessment Inventory (PAI-BOR; Distel, De Moor,
& Boomsma, 2009); personality functioning as assessed by the
Severity Indices of Personality Problems-Short Form (SIPP;
Verheul, 2006; Verheul et al. 2008); interpersonal problems as
assessed by the Inventory of Interpersonal Problems (IIP;
Horowitz, Alden, Wiggins, & Pincus, 2000; Zevalkink et al.
2012); quality of life as assessed by the EQ-5D-3L (Brooks,
Rabin, & de Charro, 2003); and frequency of suicide attempts
and self-harm as assessed by the Suicide and Self-Harm
Inventory (SSHI; Bateman and Fonagy, 2004). The intensity of
care consumption during the follow-up period was based on
the registered number of minutes of treatment at the research
sites. To exclude terminative or administrative visits related to
the previous intensive treatment phase from counting towards
additional care consumption, a minimum of 180 registered treat-
ment minutes after termination of the intensive treatment was
assumed to be relevant care consumption.
Treatment interventions
A detailed description of MBT-DH and MBT-IOP is provided
elsewhere (Smits et al., 2019). Briefly, treatment components and
features in MBT-DH and MBT-IOP are very similar, with
weekly individual sessions in both programs, but the intensity of
group therapy differs markedly. MBT-IOP involves two group
therapy sessions per week, while MBT-DH entails a day hospital
program 5 days per week, with nine group therapy sessions per
week. Treatment adherence to the MBT model in the intensive
treatment phase was rated as adequate by three independent raters
and did not differ between MBT-DH and MBT-IOP. Overall
dropout rate during the intensive treatment phase was 12%,
n = 14, comprising one-sided termination of treatment by the
patient (n = 12) or push-out by staff (n = 2), with no differences
between the groups [n = 5, 11% for MBT-IOP and n = 9, 13% for
MBT-DH; χ2(1) = 0.056, p = 0.813]. The duration of the
main treatment phase was somewhat shorter in MBT-DH
(mean = 14.3 months, S.D. = 4.2) compared with MBT-IOP
[mean = 15.9 months, S.D. = 3.1; t(109) = 2.223, p = 0.028]. There
were no differences between the groups in the proportion of
patients using medication at baseline [χ2(1) = 0.001, p = 0.972], at
18-month follow-up [χ2(1) = 2.276, p = 0.131] or 36-month
follow-up [χ2(1) = 0.185, p = 0.667].
After termination of the intensive treatment phase, patients
were offered individually tailored follow-up care generally consist-
ing of individual booster sessions of mentalizing therapy, crisis
management or psychiatric consultation, as detailed in the MBT
manual (Bateman, Bales, & Hutsebaut, 2014). Overall, 76.3%
(n = 87) of patients received such care at their initial treatment
site after ending the intensive treatment phase, with a trend for
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patients in MBT-DH to more often receive follow-up care (n = 58,
82.9%) than patients in MBT-IOP [n = 29, 65.9%; χ2(1) = 3.41,
p = 0.065]. Additionally, for patients who received follow-up
care, the intensity of this care was significantly higher in
the MBT-DH group (median = 82 h) than in the MBT-IOP
group (median = 51 h; Mann–Whitney U = 1049.00, z = –2.04,
p = 0.041), with large individual variability in both groups
(range 3–350 h).
Statistical analyses
Differences in demographic and clinical features at baseline were
investigated using two-tailed χ2 tests and independent sample t
tests, as appropriate. Mann–Whitney U tests were used to exam-
ine differences in follow-up care consumption.
Multilevel modelling was used to examine treatment outcomes
over time to best accommodate the missing data that are an inev-
itable feature of longitudinal follow-up and to deal with the
dependency of repeated measures within subjects over time; this
was conducted using the XTMIXED procedure of Stata
Statistical Software Release 12. All outcome analyses were based
on the intention-to-treat principle. Time points were coded −6,
−5, −4, −3, −2, −1 and 0, implying that regression coefficients
involving time measured the rate of change from baseline to
36-month follow-up and regression intercepts referenced group
differences at the last time point. SSHI scores were log-
transformed because they were positively skewed. Maximum like-
lihood was used to assess whether random or fixed slopes should
be assumed in models for each outcome variable. Subsequently,
quadratic and cubic time variables were added to the model if
likelihood ratio tests showed a significant improvement in fit.
In interpreting the multilevel models, a significant main effect
of time(polynomials) represents significant differences over the
course of time independent of group; intercepts reference poten-
tial significant group differences at 36 months after the start of
treatment. Finally, significant interaction effects between group
Fig. 1. CONSORT flow diagram. MBT-DH, day hospital mentalization-based treatment; MBT-IOP, intensive outpatient mentalization-based treatment.
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and (any polynomial of) time represent significant differences in
the slopes of MBT-DH compared with MBT-IOP, and hence sig-
nificant differences in the trajectories of change over time.
Reported estimates and Cohen’s d effect sizes (Cohen, 1988)
were based on predicted values. The a priori set superiority mar-
gin was d⩾ 0.50, as this represents a clinically meaningful differ-
ence in the treatment of BPD (Laurenssen et al., 2018; Smits et al.,
2019). Furthermore, clinically significant change was calculated
for symptom severity and borderline symptomatology. Patients
were classified into the following categories: (1) recovered
(i.e. statistically reliable change and movement from a dysfunc-
tional range to a functional range), (2) improved (i.e. statistically
reliable change in the direction indicative of improvement without
crossing the cut-off); (3) unchanged (i.e. no statistically reliable
change), (4) deteriorated (i.e. statistically reliable change in the
opposite direction to that indicative of improvement) and (5)
relapsed (i.e. statistically reliable change in the opposite direction
to that indicative of improvement and movement from a func-
tional to a dysfunctional range). To deal with missing data, recov-
ery scores were based on predicted estimates of multilevel
modelling. Following Jacobson and Truax (1991), reliable change
(RC) from baseline to 18 months, baseline to 36 months and 18–
36 months after the start of treatment was computed based on the
formula RC = 1.96 ×√2(S.E.)2. To calculate the standard error of
measurement (S.E.), Cronbach’s α of 0.97 was used for the BSI
(De Beurs, 2011) and 0.81 for the PAI-BOR (Distel et al., 2009)
based on the following formula: S.E. =√(1-α). The cut-off
score for movement from a dysfunctional to a normative range
was based on the following formula: [(S.D.normal ×Mclinical) +
(S.D.clinical ×Mnormal)]/(S.D.normal × S.D.clinical). Means and standard
deviations for the clinical and non-clinical populations were
based on values reported in the manual of the Dutch version of
the BSI (De Beurs, 2011). For the PAI-BOR, means and standard
deviations for the non-clinical population were based on norms of
Distel et al. (2009), and respective values for the clinical popula-
tion were based on our own sample. Owing to missing data, clin-
ically significant change could not be computed for all
participants: it was computed for n = 112 participants on the
BSI and n = 111 on the PAI-BOR (Table 1). The χ2 tests were
used to determine whether MBT-DH and MBT-IOP differed in
terms of recovery as calculated from baseline to 36 months after
the start of treatment and from 18 to 36 months.
Randomization, missing data and sensitivity analyses
There were no significant differences between the two treatment
groups at baseline, except for a higher percentage of patients
who reported self-harm at baseline in MBT-IOP (63%) compared
with MBT-DH (42%), χ2(1) = 3.96, p < 0.001. The proportion of
missing data increased somewhat with each follow-up assessment
owing to difficulties in contacting patients who were no longer in
treatment, and ranged from 53% to 58% depending on the out-
come measure and follow-up time point. Overall, 61% of patients
completed at least one of the three follow-up assessments on the
primary outcome measure. There was no difference between
MBT-IOP and MBT-DH in terms of the number of patients
who completed at least one follow-up assessment: n = 27 (61%)
for MBT-IOP and n = 42 (60%) for MBT-DH [χ2(1) = 0.021,
p = 0.885]. There were also no significant baseline differences
between patients who completed a follow-up assessment and
those who did not. This suggests that there was no selective
study drop-out as a function of baseline severity.
Although multilevel modelling is quite robust in dealing with
missing data, we re-ran all analyses using state-of-the-art data
imputation procedures as described in Smits et al. (2019). These
analyses yielded similar results, hence only results on the non-
imputed data set are reported. Results on the imputed data are
available upon request from the first author.
We also performed completer analyses, excluding treatment
drop-outs using the pre-defined criterion of one-sided termin-
ation of treatment by the patient or push-out by staff (n = 14).
These analyses yielded similar results as the intention-to-treat
analyses for all outcome measures (see online Supplemental
Table S1).
Results
Primary outcome
Improvement over time in terms of symptom severity between
baseline and 36-month follow-up was statistically significant,
representing large effect sizes in both MBT-IOP (d = 1.00) and
MBT-DH (d = 1.12). There was no significant difference
between the two groups at 36 months after the start of treatment
[β = –0.20, 95% CI (–0.62 to 0.22), z = –0.93, p = 0.350], nor did
the rate of change differ between the two groups [β = –0.02,
95% CI (–0.09 to 0.05), z = –0.51, p = 0.610]. The between-group
effect size of d = 0.26 also indicated that MBT-DH was not super-
ior to MBT-IOP in terms of improvement in symptom severity
based on the a priori specified clinically meaningful Cohen’s
d⩾ 0.5 margin at 36 months after the start of treatment
(Table 1) (Fig. 2).
Secondary outcomes
Likewise, no significant differences were observed for any of the
secondary outcome measures between the two groups at 36
months after the start of treatment (Table 1). Between-group
effect sizes were small, with the exception of quality of life as mea-
sured with the EQ-5D-3L. Patients in MBT-DH showed higher
scores than patients in MBT-IOP on this measure (d = 0.55),
although this difference did not reach significance in the multi-
level model. Yet, significant interaction effects between time(poly-
nomials) and group indicated significant differences in terms of a
differential rate of change between patients in MBT-DH and
MBT-IOP on several other secondary outcome variables, suggest-
ing differences in trajectories of improvement between the treat-
ment groups. This was the case for several domains of
personality functioning as assessed by the SIPP (identity integra-
tion, self-control, and relational capacities), borderline symptom-
atology as assessed by the PAI-BOR, and interpersonal problems
as assessed by the IIP (Table 1). For all these secondary outcome
measures, patients in MBT-DH maintained treatment gains made
in the first 18 months of treatment or showed small additional
gains, as represented by small within-group effect sizes from
18- to 36-month follow-up (range d = –0.08 to 0.24). Patients in
MBT-IOP, by contrast, showed clear continued improvement on
these outcome measures during the follow-up period, as is also
shown by medium within-group effect sizes between 18 and 36
months (range d = 0.29–0.56). For relational functioning (SIPP
relational capacities and IIP interpersonal problems), patients in
MBT-IOP even showed a larger improvement during the
follow-up period compared with the active treatment phase,
whereas patients in MBT-DH did not show continued
4 Maaike L. Smits et al.
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Table 1. Predicted means, results from multilevel models and effect sizes 36 months after the start of treatment on primary and secondary outcome measures for patients randomly assigned to intensive outpatient
mentalization-based treatment (MBT-IOP) (n = 44) or day hospital mentalization-based treatment (MBT-DH) (n = 70)
Symptom severity (GSI) Identity integration (SIPP) Self-control (SIPP)
MBT-IOP MBT-DH MBT-IOP MBT-DH MBT-IOP MBT-DH
M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI
Baseline 1.97 1.84–2.11 1.88 1.78–1.97 1.88 1.76–1.99 1.86 1.79–1.94 2.05 1.95–2.15 2.16 2.08–2.23
18 months 1.45 1.25–1.64 1.30 1.16–1.44 2.34 2.13–2.54 2.64 2.78–2.50 2.57 2.40–2.74 2.86 2.75–2.98
36 months 1.36 1.11–1.61 1.16 0.96–1.36 2.71 2.43–2.99 2.59 2.36–2.81 2.88 2.64–3.13 3.00 2.82–3.19
Model: Wald χ2 69.26 (df = 4) 96.82 (df = 6) 104.31 (df = 5)
Linear change −0.04 −0.05 to −0.14 p = 0.352 0.25* 0.05–0.47 p = 0.016 0.09* 0.01–0.18 p = 0.032
Quadratic change −0.02*** −0.09 to 0.05 p < 0.001 −0.07 −0.14 to 0.01 p = 0.069 – – –
Cubic change – – – 0.01* 0.00–0.02 p = 0.037 0.00 −0.00 to 0.00 p = 0.138
Δ Linear change −0.02 −0.09 to 0.05 p = 0.610 −0.27** −0.44 to −0.10 p = 0.002 – – –
Δ Quadratic change – – – 0.04** 0.02–0.07 p = 0.001 – – –
Δ Cubic change – – – – – – 0.00* 0.00–0.00 p = 0.048
Δ Group 36 months −0.20 −0.62 to 0.22 P = 0.350 −0.13 −0.60 to 0.35 p = 0.606 0.12 −0.30 to 0.54 p = 0.576
Within-group ES
(baseline–18/18–36 months)
0.86/0.12 1.04/0.21 0.80/0.49 1.58/–0.08 1.07/0.49 1.61/0.24
(Baseline–36 months) 1.00 1.12 1.45 1.15 1.71 1.54
Between-group ES (18/36 months) 0.24/0.26 0.50/0.15 0.57/0.17
Social concordance (SIPP) Responsibility (SIPP) Relational capacities (SIPP)
MBT-IOP MBT-DH MBT-IOP MBT-DH MBT-IOP MBT-DH
M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI
Baseline 2.63 2.53–2.73 2.75 2.68–2.83 2.49 2.37–2.61 2.67 2.60–2.75 2.29 2.15–2.42 2.16 2.08–2.24
18 months 2.81 2.65–2.97 3.00 2.89–3.11 2.74 2.55–2.92 2.86 2.74–2.97 2.41 2.21–2.61 2.58 2.46–2.70
36 months 2.99 2.78–3.20 3.25 3.11–3.39 2.98 2.76–3.21 3.04 2.88–3.20 2.54 2.29–2.79 2.58 2.41–2.75
Model: Wald χ2 41.06 (df = 3) 43.27 (df = 3) 37.30 (df = 5)
Linear change 0.06** 0.02–0.10 p = 0.001 0.08*** 0.05–0.12 p < 0.001 0.08 –0.02 to 0.19 p = 0.135
Quadratic change – – – – – – –0.00 –0.02 to 0.01 p = 0.570
Δ Linear change 0.02 –0.03 to 0.07 p = 0.362 –0.02 –0.07 to 0.02 p = 0.337 –0.15* 0.29 to –0.01 p = 0.033
Δ Quadratic change 0.03** 0.01–0.05 p = 0.005
Δ Group 36 months 0.26 –0.05 to 0.56 p = 0.101 0.06 –0.26 to 0.37 p = 0.728 −0.04 –0.18 to 0.86 p = 0.859
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Table 1. (Continued.)
Symptom severity (GSI) Identity integration (SIPP) Self-control (SIPP)
MBT-IOP MBT-DH MBT-IOP MBT-DH MBT-IOP MBT-DH
M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI
Within-group ES
(baseline–18/18–36 months)
0.38/0.32 0.59/0.53 0.45/0.39 0.15/0.62 0.21/0.29 0.91/0.00
(Baseline–36 months) 0.77 1.09 0.90 0.75 0.55 0.79
Between-group ES
(18/36 months)
0.40/0.45 0.00/0.09 0.29/0.05
Borderline symptomatology (PAI-BOR) Quality of life (EQ-5D-3L) Interpersonal problems (IIP)
MBT-IOP MBT-DH MBT-IOP MBT-DH MBT-IOP MBT-DH
M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI M 95% CI
Baseline 49.61 48.14–51.09 47.52 46.32–48.73 0.44 0.41–0.47 0.48 0.45–0.51 108.44 103.74–113.15 108.95 105.48–112.42
18 months 40.07 38.15–43.24 33.91 33.35–37.23 0.60 0.55–0.64 0.66 0.63–0.69 105.29 96.27–114.31 89.75 83.07–96.42
36 months 35.42 31.77–39.07 32.95 29.92–35.97 0.61 0.56–0.66 0.69 0.65–0.73 90.94 77.58–104.30 87.74 77.05–98.43
Model: Wald χ2 116.44 (df = 5) 44.68 (df = 4) 19.44 (df = 5)
Linear change –1.56* –3.01 to –0.10 p = 0.036 −0.00 −0.03 to 0.03 p = 0.816 –6.65 –14.47 to 1.17 p = 0.096
Quadratic change – – – – – – 0.62 –0.51 to 1.76 p = 0.283
Cubic change –0.02 –0.05 to –0.01 p = 0.160 0.00** 0.00–0.00 p = 0.007
Δ Linear change –1.32 –0.55 to 3.20 p = 0.165 0.01 –0.02 to 0.03 p = 0.606 –8.85 –1.31 to 19.00 p = 0.088
Δ Quadratic change – – – – – – –1.58* –3.05 to 0.10 p = 0.036
Δ Cubic change –0.04 –0.08 to 0.00 p = 0.061 – – – – – –
Δ Group 36 months –2.47 –9.26 to 4.31 p = 0.475 0.08 –0.04 to 0.20 p = 0.199 –3.20 –28.28 to 21.87 p = 0.802
Within-group ES
(baseline–18/18–36 months)
1.23/0.56 1.68/0.24 1.10/0.09 1.34/0.24 0.12/0.40 0.81/0.00
(Baseline–36 months) 1.95 1.63 1.20 1.57 0.67 0.70
Between-group ES 0.66/0.23 0.43/0.56 0.53/0.08
Frequency of self-harm (SSHI) Frequency of suicide attempts (SSHI)
MBT-IOP MBT-DH MBT-IOP MBT-DH
Log M 95% CI Log M 95% CI Log M 95% CI Log M 95% CI
Baseline 1.63 1.38–1.87 0.89 0.70–1.08 0.17 0.09–0.24 0.22 0.11–0.20
18 months 0.33 0.09–0.56 0.42 0.24–0.59 0.19 0.02–0.15 0.13 0.05–0.12
36 months 0.27 0.11–0.42 0.41 0.290–0.53 0.11 0.00–0.07 0.04 0.00–0.02
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improvement from 18 to 36 months after the start of treatment, in
terms of effect sizes.
Clinically significant change
In terms of symptom severity as assessed by the BSI, for the two
treatment groups combined, 83% of patients (n = 93) were cate-
gorized as improved at 36-month follow-up, over a quarter of
whom (n = 25, 26.9%) were classified as recovered. A small pro-
portion of patients (n = 16, 14.3%) did not show reliable change
and three patients (2.7%) deteriorated over the course of the
36-month follow-up period. There were no differences between
MBT-IOP and MBT-DH at 18 months [χ2(2, n = 112) = 1.75, p
= 0.418] or 36 months [χ2(3, n = 112) = 5.43, p = 0.143] after the
start of treatment in terms of clinically significant change.
Looking specifically at the follow-up period from 18 to 36
months, 95 patients maintained their initial improvement
(84.8% unchanged), 12 patients continued to improve with add-
itional reliable change (10.7%) and four patients deteriorated
(3.6%). There were no significant differences in clinically signifi-
cant change from 18 to 36 months between MBT-DH and
MBT-IOP [χ2(3, n = 112) = 1.6816, p = 0.641] (Table 2).
In terms of borderline symptomatology (PAI-BOR), nearly all
patients (n = 108, 97.3%) improved at 36-month follow-up, more
than 50% of whom (n = 60, 55.6%) could be classified as recov-
ered. Three patients who had shown improvement at 18 months
after the start of treatment showed deterioration at 36-month
follow-up. There were no differences between MBT-IOP and
MBT-DH at 18 months [χ2(1, n = 111) = 1.33, p = 0.248] or 36
months [χ2(3, n = 111) = 3.18, p = 0.204] after the start of treat-
ment in terms of clinically significant change on the PAI-BOR.
Looking specifically at the follow-up period from 18 to 36
months, 89 patients showed additional reliable change (80.1%
improved or recovered), 11 patients (9.9% unchanged) main-
tained their initial improvement and 11 patients (9.9%) showed
deterioration, among whom one patient relapsed. Over the
follow-up period from 18 to 36 months, MBT-DH and
MBT-IOP differed significantly in terms of clinically significant
change on borderline symptomatology [χ2(4, n = 111) = 15.70,
p = 0.003], with more patients in MBT-IOP showing continued
improvement or recovery during follow-up [n = 39, 92.9%
improved or recovered in MBT-IOP v. n = 50, 72.4% in
MBT-DH; χ2 (1) = 7.7021, p = 0.006]. This observation is consist-
ent with findings from the multilevel models indicating that
patients in MBT-IOP showed greater continued improvement
during the follow-up period than patients in MBT-DH (Table 2).
Discussion
Patients in both MBT-DH and MBT-IOP maintained the sub-
stantial improvements made during the intensive treatment
phase, and continued to improve during long-term follow-up
from 18 to 36 months after the start of treatment. In terms of clin-
ically significant change on the primary outcome measure of
symptom severity, 83% of patients improved over this period,
over a quarter of whom (26.9%) met criteria for recovery – that
is, they moved from a dysfunctional to a functional range on
symptom severity. For borderline symptomatology specifically,
97% of patients improved, and over half of these patients could
be classified as recovered. Contrary to our hypothesis, but consist-
ent with the outcome results at 18 months, MBT-DH did not
show superiority in terms of reduction of symptom severity at
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36 months after the start of treatment. Similarly, there were no
apparent differences between the two groups in terms of clinically
significant change over the course of 36 months for both symp-
tom severity and borderline symptomatology. The trend towards
superiority of MBT-DH on several secondary outcome measures,
specifically those in the domain of relational functioning,
observed at 18 months after the start of treatment, was no longer
evident at 36 months.
Furthermore, trajectories of change during follow-up were not-
ably different for patients in MBT-DH and MBT-IOP. Patients in
MBT-DH tended to show the largest improvement during the
intensive treatment phase, and these gains were largely main-
tained or slightly increased during the follow-up period. By con-
trast, whereas the rate of improvement in MBT-IOP was smaller
than that in MBT-DH during the first 18 months, patients in
MBT-IOP showed larger additional gains during follow-up.
In other words, patients in MBT-IOP caught up with patients
in MBT-DH during follow-up. This differential trajectory of
change was most apparent in the domain of relational function-
ing, with MBT-DH patients showing faster improvement initially
that seemed to level off during follow-up, whereas MBT-IOP
patients showed a larger improvement during follow-up. This
finding is consistent with our earlier hypothesis (Smits et al.,
2019), based upon work by Fonagy, Luyten, and Allison (2015),
that the ‘safety net’ and scaffolding provided by the day hospital set-
ting may result in earlier improvements in mentalizing and social
learning because it may provide patients with greater opportunity
to generalize therapeutic gains within a relatively safe social context.
In contrast, patients in MBT-IOP are less likely to have access to a
supportive environment, and they may have to face everyday pro-
blems related to relationships, work and social activities sooner
than patients in a day hospital program. Consequently, it may
take more time for ‘virtuous cycles’ associated with increasing men-
talizing and social learning to emerge for these patients. However,
once these cycles are established, these patients seem to be able to
catch up with patients in MBT-DH.
Importantly, the greater improvements in MBT-IOP during
the follow-up period were not related to a higher intensity of
follow-up care. In fact, patients in MBT-DH received follow-up
care more often and at a higher intensity than those in
MBT-IOP. Taken together, from a developmental psychopath-
ology perspective, these results suggest that recovery in patients
in MBT-IOP may follow a more ‘natural’ course, with patients
being challenged from the start of treatment to generalize the cap-
acities they acquire in terms of mentalizing, attachment and social
learning to their everyday life. Patients in MBT-DH, by contrast,
may show faster improvement in these capacities because they
mainly function within a relatively protected environment, but
then may face the same problem when they are no longer in
the day hospital setting – that is, how to generalize what they
have learned in treatment to dealing with the everyday challenges
of life. Further research is needed to investigate these hypotheses.
There are important limitations that should be kept in mind
when interpreting the current results. First, the proportions of
missing data at the 24-, 30- and 36-month follow-up points
were substantial, although this limitation is somewhat mitigated
by the fact that imputation analysis showed comparable results.
Moreover, there were no differences in the percentages of missing
data between the two treatment groups, and completer analyses
showed similar results. Yet, it cannot be ruled out that missing-
ness might be related to factors related to treatment outcome.
Second, the superiority margin set in this trial corresponded to
a medium effect size. It could be argued that smaller
between-group differences may be clinically relevant; further
research in larger samples is needed to address this issue. Third,
there was some evidence for differential care consumption
between MBT-IOP and MBT-DH after the end of the main treat-
ment phase. However, we do not have systematic data on the exact
nature of the care that was provided at the treatment sites during
follow-up, or on in-session adherence to the MBT model outside
the main treatment phase, although the same therapists were
involved in providing care during follow-up as in the main treat-
ment phase. In addition, we did not use data on treatment-
seeking outside the treatment site for this study. This issue will
be addressed in more detail in future cost-effectiveness analyses.
Finally, use of medication may have influenced treatment
Fig. 2. Observed and predicted Global Severity Index
scores from baseline to 36 months after the start of
treatment for intensive outpatient mentalization-
based treatment (MBT-IOP) (n = 44) and day hospital
mentalization-based treatment (MBT-DH) (n = 70) with
95% confidence intervals.
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Table 2. Distribution over categories of recovery based on symptom severity (GSI) and borderline symptomatology (PAI-BOR) for patients randomly assigned to intensive outpatient mentalization-based treatment
(MBT-IOP) or day hospital mentalization-based treatment (MBT-DH)
Baseline–18 months Baseline–36 months 18–36 months
GSI
MBT-IOP
(n = 43)
MBT-DH
(n = 69)
Total
(n = 112)
MBT-IOP
(n = 43)
MBT-DH
(n = 69)
Total
(n = 112)
MBT-IOP
(n = 43)
MBT-DH
(n = 69)
Total
(n = 112)
Recovered, n (%) 5 (11.6) 11 (15.9) 16 (14.3) 8 (18.6) 17 (24.6) 25 (22.3) 2 (4.7) 3 (4.3) 5 (4.5)
Improved, n (%) 30 (69.8) 51 (73.9) 81 (72.3) 26 (60.5) 42 (60.9) 68 (60.7) 1 (2.3) 6 (8.7) 7 (6.3)
Unchanged, n (%) 8 (18.6) 7 (10.1) 15 (13.4) 9 (20.9) 7 (10.1) 16 (14.3) 39 (90.7) 56 (82.2) 95 (84.8)
Deteriorated, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 3 (4.3) 3 (2.7) 1 (2.3) 3 (4.3) 4 (3.6)
Relapsed, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PAI-BOR (n = 42) (n = 69) (n = 111) (n = 42) (n = 69) (n = 111) (n = 42) (n = 69) (n = 111)
Recovered, n (%) 19 (45.2) 39 (56.5) 59 (53.2) 22 (52.4) 38 (55.1) 60 (54.1) 2 (4.8) 0 (0) 2 (1.8)
Improved, n (%) 23 (54.8) 30 (43.5) 53 (47.7) 20 (47.6) 28 (40.6) 48 (43.2) 37 (88.1) 50 (72.5) 87 (78.4)
Unchanged, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (7.1) 8 (11.6) 11 (9.9)
Deteriorated, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 3 (4.3) 3 (2.7) 0 (0) 10 (14.5) 10 (9.0)
Relapsed, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.4) 1 (0.9)
MBT-IOP, intensive outpatient mentalization-based treatment; MBT-DH, day hospital mentalization-based treatment; GSI, Global Severity Index of the Brief Symptom Inventory; PAI-BOR, Personality Assessment Inventory – Borderline Personality
Disorder section.
Recovery scores are calculated between baseline and 18 months, between baseline and 36 months, and between 18 and 36 months after the start of treatment. Recovered, statistically reliable change and movement from a dysfunctional range to a
functional range. Improved, statistically reliable change in the direction indicative of improvement without crossing cut-off. Unchanged, no statistically reliable change. Deteriorated, statistically reliable change in the opposite direction of that indicative
of improvement. Relapsed, statistically reliable change in the opposite direction of that indicative of improvement and movement from a functional to a dysfunctional range.
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outcomes, although there were no differences between the two
treatment arms in the proportion of patients using medication
at baseline or 18 or 36 months after the start of treatment.
Despite these limitations, the results of this study suggest that
MBT-IOP and MBT-DH are both valuable treatment options for
patients with BPD. However, cost-effectiveness analyses are
needed, given the large differences in intensity and cost of the
two treatments, to further investigate whether MBT-IOP is
more cost-effective than MBT-DH. As observations from an
organizational perspective have shown that MBT-DH is more dif-
ficult to implement (Bales, Verheul, & Hutsebaut, 2017), without
support for its cost-effectiveness, it will be hard to maintain
MBT-DH as a viable treatment option. In terms of the optimiza-
tion of use of health care resources, the implementation of less
intensive treatment programs might enable more patients to be
treated with similar resources, reducing the iatrogenic harm
related to the choice of less ideal treatment options or long wait-
ing lists. Still, however, MBT-DH may be more (cost-)effective in
specific subgroups of BPD patients (e.g. those with more severe
and chronic psychosocial problems), including those for whom
MBT-IOP might even be contraindicated. Therefore, more
research is needed to identify potential factors that might predict
differential treatment outcomes. For example, for patients who are
highly chaotic and fragmented, the stronger holding environment
and structure provided by an intensive day hospital setting may be
more effective than an outpatient setting. On the basis of the cur-
rent results, we also hypothesize that an assessment of the social
environment and opportunities for creating a sufficiently benign
context in which treatment gains can be generalized might be
important to consider when determining which treatment is likely
to work best for individual patients.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291720002123.
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